Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety

Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for...

Descripción completa

Detalles Bibliográficos
Autor principal: Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156204/
https://www.ncbi.nlm.nih.gov/pubmed/30249170
http://dx.doi.org/10.1177/1753466618801167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156204/
https://www.ncbi.nlm.nih.gov/pubmed/30249170
http://dx.doi.org/10.1177/1753466618801167

Ejemplares similares